• LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE
• ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND MANUFACTURING
• EXPANSION OF MANAGEMENT BOARD WITH NEW CHIEF BUSINESS OFFICER (CBO) DR MATTHIAS EVERS AS EXPERT IN AI/ML DRIVEN PROCESSES

HAMBURG, GERMANY / ACCESSWIRE / March 2, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) today presents at its virtual Capital Markets Day how artificial intelligence ("AI") and machine learning ("ML") enabled precision technologies in discovery and development processes are driving up Probability of Success ("PoS"), i.e. an increasing rate of approvals in the long-run.

To leverage the power of molecular data, Evotec is launching E.MPD, the Company's molecular patient database. E.MPD is one of the largest and highest quality molecular databases globally.

Evotec's integrated technology platforms show that the best way to effectively treat disease is to identify underlying disease mechanisms and find the most suitable therapy on the basis of molecular data guiding all experimental processes towards early disease relevance. Therefore, data aggregation, integration, and the precise analysis of data is the critical path to effective and affordable medicine in the future.

With E.MPD, Evotec integrates another key offering into its data-driven R&D Autobahn to Cures. E.MPD will serve as the backbone for data-driven partnerships that will lead to innovative new medicines, better patient stratification, and potentially pave the way towards a new paradigm of more effective diagnostic and preventative healthcare. Through gathering and analysing patient-derived data in combination with AI/ML tools, Evotec is also able to better predict both safety and efficacy indicators in drug development.

At its virtual Capital Markets Day, Evotec gives an overview of its unique business strategy to become the world's leading precision medicine platform for modality-agnostic development of innovative therapeutic approaches. Built on partnerships, this strategy leads the way for a large co-owned pipeline.

Highlights include:

• Confirmation of Action Plan 2025 goals and progress update
• AI/ML driven drug discovery and development process examples resulting in multiple new partnerships, including the initiation of multiple projects in the recently opened J.POD ^(R) manufacturing facility for modern biologics in Redmond, WA (USA)
• Novel drug discovery platform and modality highlights (e.g. iPSC technologies, AI/ML driven safety prediction, integrated AI/ML driven drug design E.INVENT-AI, and RNA technologies)

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are pleased to present some highlights and breakthroughs of the scientific power of our proprietary platforms today. The potential of our high-tech R&D platforms is enormous, just at the beginning, and fundamental for a precise and affordable healthcare system of the future. Only by bringing up Probabilities of Success ("PoS") we can massively impact the returns from R&D investments and make more precise medicine accessible to all patients."

In order to ensure continuation of the growth witnessed in recent years, and to further accelerate data-driven development, Evotec is adding a new member to the Management Board. Starting as of 02 May 2022, Dr Matthias Evers, will serve as Chief Business Officer. Currently, Dr Evers is Senior Partner and global co-lead of R&D in Life Sciences at McKinsey & Company. Biochemist and bioinformatician by training, Matthias has developed innovation strategies for life science companies worldwide, built functional capabilities required for sustainable productivity gains in research and development, and driven collaboration across public and private partners in search of accelerated patient impact. As Chief Business Officer, Matthias will take on responsibility for business development, digital/technology, and strategy.

Dr Matthias Evers, Senior Partner at McKinsey, said : "I have spent my career as a scientist and consultant in life sciences on exploiting the confluence of biology, chemistry, and technology more broadly, i.e., data, AI/ML as well as automation. Evotec's platform is uniquely positioned - like one can see in the iPSC space as one example - to capitalise on this opportunity as we enter a new era of science and disease understanding. After 20 years in impact consulting at McKinsey, I am thrilled to join the very strong Evotec team to grow its platform globally and realise its ultimate promise for patients."

"As a proven thought leader of innovation in the field of AI/ML driven science, Matthias will make an important contribution with his expertise and experience to our network of partners," added Dr Werner Lanthaler, Chief Executive Officer of Evotec . "On behalf of our whole Team and company, we very much look forward to working with Matthias and wish him a great start."

About the virtual Capital Markets Day

Evotec will host its virtual Capital Markets Day on 02 March 2022, starting at 8.00 am EST (2.00 pm CET, 1.00 pm GMT). The meeting will take place via a live webcast and a recording will be available on www.evotec.com .

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG